Clinical trials: Kidney Failure,Chronic
Renal Insufficiency, Chronic, Hyperkalemia
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's…
- Trial name
- STABILIZE-CKD (NCT05056727)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Lisinopril, Valsartan
- Where
- 276 sites in United States, Argentina and 19 more
- Volunteers
- 1,112 people
- Sponsor
- AstraZeneca
Renal Failure Chronic, Hepatitis C
Multi-center Study to Transplant Hepatitis-C Infected Kidneys
Open label multi center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- MYTHIC (NCT03781726)
- Testing
- glecaprevir/pibrentasvir treatment
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Raymond Chung
End Stage Renal Disease
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
A few studies have reported erythropoiesis-stimulating agent (ESA) doses before and after 25D supplementation, but only one of these is a prospective clinical trial, and it is a small, single center study lacking a control arm.
- Trial name
- NCT01395823
- Testing
- ergocalciferol supplementation
- Where
- 12 sites in United States
- Volunteers
- 470 people
- Sponsor
- Dialysis Clinic, Inc.
Chronic Renal Failure
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
This is a study to investigate the efficacy and safety of OPC-41061 by 24-week oral administration of OPC-41061 at 15-mg or 30-mg or placebo in patients with chronic renal failure who are undergoing hemodialysis or…
- Trial name
- NCT02331680
- Testing
- OPC-41061
- Where
- 4 sites in Japan
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Chronic Kidney Diseases, Cystic Kidney Disease
Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension
The purpose of this research study is to evaluate contrast-enhanced ultrasound for kidney malignancies.
- Trial name
- CEUS-CKDx (NCT03196076)
- Testing
- Perflutren Lipid microsphere
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Kidney Failure, Chronic
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
The purpose of this study is to compare the absorption of dietary phosphorus following a single dose with lanthanum carbonate (1000mg) and a single dose of sevelamer carbonate (2400mg).
- Trial name
- NCT00875017
- Testing
- Lanthanum Carbonate, Sevelamer
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Shire
Chronic Kidney Disease
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
This research study is designed to assess the safety and effectiveness of an experimental drug called vonapanitase (PRT-201) in patients both receiving or expecting to receive hemodialysis who have chronic kidney disease and who…
- Trial name
- NCT02414841
- Testing
- Vonapanitase
- Where
- 41 sites in United States, Canada
- Volunteers
- 696 people
- Sponsor
- Proteon Therapeutics
Gout, Chronic Kidney Diseases
CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attacks. These therapies have never been compared at appropriate doses.
- Trial name
- NCT02579096
- Testing
- allopurinol capsule, 100-800 mg by mouth once daily, febuxostat tablet 40-120 mg by mouth once daily
- Where
- 23 sites in United States
- Volunteers
- 950 people
- Sponsor
- VA Office of Research and Development
Chronic Kidney Disease
Home-base Kidney Care in Zuni Indians
People reach End Stage Renal Disease (ESRD) due to progressive chronic kidney disease (CKD). CKD is associated with increased risks for heart disease and death.
- Trial name
- HBKC (NCT02915029)
- Testing
- Educational and lifestyle coaching
- Volunteers
- 125 people
- Sponsor
- University of New Mexico
Kidney Transplant
Reducing Disparities in Living Donor Transplant Among African Americans
For most of the patients in the United States with end stage renal disease (ESRD), kidney transplantation represents the optimal treatment, and living donor kidney transplantation (LDKT) is preferable.
- Trial name
- NCT03819686
- Testing
- Living ACTS website, Standard transplant education procedures
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Emory University
Chronic Kidney Disease
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
The purpose of the present study is to investigate the association between the accumulation of advanced glycation end-products (AGE) and adverse outcomes (e.g.
- Trial name
- AGED (NCT02878317)
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- University of Nottingham
Infections, Bacterial
Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function
This study will be conducted to determine if altered renal function affects the plasma pharmacokinetics of gepotidacin, which will inform if dosing recommendations based upon renal impairment are required.
- Trial name
- NCT02729038
- Testing
- Gepotidacin
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Renal Insufficiency, Type 2 Diabetes Mellitus
A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)
This is a 2-part study in participants with renal impairment and matched healthy participants to investigate the effect of impaired renal function on the plasma and urine levels of omarigliptin (MK-3102) after taking a single 3…
- Trial name
- NCT01407276
- Testing
- Omarigliptin
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Anemia Associated With Chronic Kidney Disease (CKD)
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for the maintenance treatment of…
- Trial name
- NCT04707768
- Testing
- Vadadustat, Mircera®
- Where
- 58 sites in United States
- Volunteers
- 456 people
- Sponsor
- Akebia Therapeutics
Chronic Kidney Diseases, Endothelial Dysfunction
Resveratrol and Vascular Function in CKD
The proposed research is clinical study evaluating the therapeutic benefits of resveratrol on vascular function in patients with chronic kidney disease (CKD).
- Trial name
- NCT03597568
- Testing
- Resveratrol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Diana Jalal
Chronic Renal Failure, Chronic Kidney Disease
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA)…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- PEARL 1 (NCT00598273)
- Testing
- peginesatide, Darbepoetin alfa
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 490 people
- Sponsor
- Affymax
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
End Stage Renal Disease, Acute Kidney Injury
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
Hemodialysis is a therapy that filters waste, removes extra fluid and balances electrolytes. In hemodialysis, blood is removed from the body and filtered through a man-made membrane called a dialyzer, and then the filtered blood…
- Conditions
- End Stage Renal Disease, Acute Kidney Injury, Chronic Kidney Disease Stage 5
- Trial name
- ESRD (NCT03539861)
- Testing
- Hemodialysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Michigan
End Stage Renal Disease
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
To characterize the GORE® Hybrid Vascular Graft as compared to non-heparin bonded synthetic vascular grafts in terms of the prevalence and persistence of anti-platelet factor 4 / heparin antibodies (anti-PF4 / H antibodies).
- Trial name
- NCT02165761
- Testing
- GORE® Hybrid Vascular Graft, Non-heparin bonded synthetic graft
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- W.L.Gore & Associates
Kidney Disease, Chronic
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice.
- Trial name
- NCT06287073
- Testing
- JARDIANCE®
- Where
- 12 sites in South Korea
- Volunteers
- 299 people
- Sponsor
- Boehringer Ingelheim